212 results
8-K
EX-99.1
SAVA
Cassava Sciences Inc
28 Feb 24
Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates
9:22am
)
Three months ended December 31,
Year Ended December 31,
Operating expenses
Research and development, net of grant reimbursement
General
424B2
SAVA
Cassava Sciences Inc
3 Jan 24
Prospectus for primary offering
4:22pm
and commercialized;
the pricing and reimbursement of our product candidates, if approved and commercialized;
the utility of protection, or the sufficiency, of our … adversely affect our product pricing or limit the reimbursement we may receive for our products.
A significant breakdown, security breach
8-K
EX-99.1
40qci2e5f 43yq
7 Nov 23
Cassava Sciences Reports Third Quarter 2023 Financial and Operating Results
9:08am
8-K
EX-3.4
txb0poz40e pg6
13 Sep 23
Amendments to Articles of Incorporation or Bylaws
4:17pm
8-K
EX-99.1
7izos niv
3 Aug 23
Cassava Sciences Reports Q2 2023 Financial Results and Operating Updates
9:12am
8-K
EX-1.1
jm6g1bk16z
1 May 23
Entry into a Material Definitive Agreement
5:26pm
424B5
y22y vvdsdtciml6
1 May 23
Prospectus supplement for primary offering
5:26pm
S-3ASR
4kluu3gffrgbjouprc
1 May 23
Automatic shelf registration
4:01pm
8-K
EX-99.1
o199t5qbiyso60
1 May 23
Cassava Sciences Reports Q1 2023 Financial Results and Operating Updates
9:05am
8-K
EX-10.1
bynelg6493t
22 Nov 22
Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock
12:49pm
424B5
08djak ktjj1p
21 Nov 22
Prospectus supplement for primary offering
8:00am
8-K
EX-99.1
py1hmjzpu2i
7 Nov 22
Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates
9:09am
8-K
EX-10.1
4re5 zfx2316wk1j
27 Oct 22
Cassava Sciences Announces Expansion of Leadership Team
4:03pm